-
4m 15sPart 3 | Session 1 The Phase 3 REVERSE-IT Trial
-
4m 3sPart 3 | Session 2 EVOLUT Low Risk: 5Y Outcomes After TAVR or SAVR in Low-Risk Patients with AS
-
4m 14sPart 3 | Session 3 SMART-CHOICE 3: Clopidogrel vs Aspirin Monotherapy in High-Risk PCI Patients
-
9m 39s
-
2m 54s
-
4m 58sPart 3 | Session 6 MIGHTy-Heart: Mobile Integrated Health in Heart Failure
-
7m 33s
-
2m 46s
-
6m 34s
-
2m 46sPart 3 | Session 10 Lifetime Benefit by Control of Modifiable Risk Factors
-
10m 27sPart 3 | Session 11 CardiAMP-HF: Autologous Cell Therapy in Patients With HFrEF
-
3mPart 4 | Session 1 4 Trials That Will Change My Practice with Dr Ambarish Pandey
-
4m 27sPart 4 | Session 2 4 Trials That Will Change My Practice with Dr Dipti Itchhaporia
-
30m 45sPart 1 | Session 1 View from the Thoraxcenter: What's Hot at ACC.25?
-
39m 2sPart 1 | Session 2 View from the Thoraxcenter: ACC 25 Wrap-Up
-
17m 26sPart 2 | Session 1 ADVANCE-HTN: Lorundrostat in Patients with Uncontrolled Hypertension
-
11m 44sPart 2 | Session 2 STRIDE: Semaglutide for Functional Capacity in Patients with T2D and PAD
-
12m 9sPart 2 | Session 3 API-CAT: Reduced Vs Full Dose Apixaban for Cancer-Associated Thrombosis
-
14m 1sPart 2 | Session 4 FRESH-UP: Liberal Intake Vs Fluid Restriction in Chronic Heart Failure
-
20m 59sPart 2 | Session 5 SOUL: Semaglutide in Patients with T2D
ACC 25 - PROTECT-TAVI shows no benefit to routine use of cerebral embolic protection during transcatheter aortic valve implantation (TAVI).
Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK) to discuss the findings from the British Heart Foundation's PROTECT-TAVI Trial, which aimed to determine whether using cerebral embolic protection (CEP) devices during TAVI procedures can reduce the risk of stroke in patients with aortic stenosis.
The study enrolled 7627 patients undergoing TAVI, who were randomly assigned to recieve either the standard procedure, or TAVI with CEP. The primary endpoint was incidence of stroke within 72 hours after TAVI procedure, and secondary endpoints were long-term patient outcomes at 12 months and the impact on the NHS healthcare system. 7635 patients scheduled for TAVI were randomized to have the procedure either with a CEP device, or without.
Findings showed no difference in stroke rate between groups, and similar results seen between groups for severe stroke and all-cause death.
Recorded Remotely from Hamilton and Oxford, 2025.
Editors: Yazmin Sadik, Jordan Rance
Videographers: David Ben-Harosh
Support: This is an independent interview produced by Radcliffe Cardiology.
Keep up-to-date with our video collection on the American College of Cardiology's 74th annual congress, covering late-breaking science, featured science and clinical horizon sessions. Don't miss the preview and wrap-up of the congress in our View From the Thoraxcenter series, concise Expert Interviews with select faculty offering take-home messages for practice, and our Highlights summarising the most influential trials.
More from this programme
Part 1
View From the Thoraxcenter
Part 2
Late-Breaker Discussion Series
Part 3
Expert Interviews
Faculty Biographies
Rajesh Kharbanda
Professor
Prof Rajesh Kharbanda, Consultant Cardiologist in Oxford, graduated from Edinburgh Medical School in 1991, and has trained and worked in the speciality of cardiology in London, Cambridge, Toronto (Canada).
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an internationally known cardiologist, research methodologist, and senior scientist. She serves as an Associate Professor of Medicine at McMaster University, a Senior Scientist at the Population Health Research Institute, and Director of Implementation Science at the Baim Institute for Clinical Research in Boston.
Academic history
Dr Van Spall completed her BSc and MD at the University of Toronto, followed by residency and fellowship training in internal medicine and…
Comments